Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation

Journal of Cardiovascular Medicine

Volumn 13, Issue 2, 2012, Pages 86-96

  Solomon, Matthew D ^a   Ullal, Aditya J ^a   Hoang, Donald D ^a   Freeman, James V ^a   Heidenreich, Paul ^a   Turakhia, Mintu P ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

atrial fibrillation; cost effectiveness; stroke; therapies

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; ATENOLOL; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DIGOXIN; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

BLEEDING; BRAIN HEMORRHAGE; CATHETER ABLATION; COST EFFECTIVENESS ANALYSIS; DEVICE THERAPY; DRUG COST; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; REVIEW; STROKE; SURVIVAL; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC SURGICAL PROCEDURES; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HEART CATHETERIZATION; HEMORRHAGE; HUMANS; PREVENTIVE HEALTH SERVICES; SEPTAL OCCLUDER DEVICE; STROKE; TREATMENT OUTCOME;

EID: 84856093393     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32834f23cf     Document Type: Review

References (40)

1. Feinberg W, Blackshear J, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.. Arch Int Med 1995; 155:469-473.
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119-125.
3. Wolf P, Benjamin E, Belanger A, et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 1996; 131:790-795. (Pubitemid 26116354)
4. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2009; 119:e21-e181.
5. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004; 43:929-935. (Pubitemid 38401065)
6. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
7. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 51:674-681.
8. Wolf P, Abbott R, Kannel W. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Int Med 1987; 147:1561-1564. (Pubitemid 17138836)
9. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123:e18-e209.
10. IOM (Institute of Medicine). A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases. Washington, DC: The National Academies Press; 2011. pp. 19-31.
11. Drummond MF, Schulpher MJ, George TW, et al. Methods for the economic evaluation of healthcare programmes. 3rd ed. Oxford: Oxford University Press; 2005.
12. Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13:322-338. (Pubitemid 24013155)
13. Kazi DS, Hlatky MA. The cost effectiveness of cardiac resynchronization therapy. In: Abraham WT, Baliga RR, editors. Cardiac Resynchronization Therapy in Heart Failure. Philadelphia: Wolters Kluwer Health Lippincott Williams & Wilkins; 2010. pp. 137-143.
14. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998; 158:1669-1677. (Pubitemid 28371191)
15. Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and costeffectiveness issues. Chest 1998; 114 (5 Suppl):699S-714S. (Pubitemid 28535790)
16. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150:73-83.
17. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154:1-11.
18. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274:1839-1845. (Pubitemid 26001259)
19. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preferencebased antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29:1083-1091. (Pubitemid 28265459)
20. Jowett S, Bryan S, Mant J, et al. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke 2011; 42:1717-1721.
21. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005; 293:699-706. (Pubitemid 40216039)
22. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011; 123:2562-2570.
23. Landefeld C, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-152. (Pubitemid 19201634)
24. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Int Med 1994; 120:897-902. (Pubitemid 24179151)
25. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153:1557-1562. (Pubitemid 23205854)
26. Investigators SESCftSV. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 2005; 293:690-698.
27. Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007; 370:493-503. (Pubitemid 47212371)
28. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. The Lancet 2003; 362:1691-1698. (Pubitemid 37468318)
29. Freeman JV, Turakhia MP. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Int Med 2011; 154:570-571.
30. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975-983.
31. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol 2006; 47:2513-2520. (Pubitemid 43866357)
32. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870. (Pubitemid 32537350)
33. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31:2369-2429.
34. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354. (Pubitemid 44252297)
35. Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009-1017.
36. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
37. Camm AJ. Quality of life in patients with atrial fibrilation. Rev Esp Cardiol 2010; 63:1393-1395.
38. Luderitz B, Jung W. Quality of life in patients with atrial fibrillation. Arch Intern Med 2000; 160:1749-1757. (Pubitemid 30418811)
39. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?. Lancet 2005; 365:82-93. (Pubitemid 40082150)
40. Black N. Why we need observational studies to evaluate the effectiveness of healthcare. BMJ 1996; 312:1215-1218. (Pubitemid 26136714)